TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSC-101 overview
TSC-101 is under development for the treatment of blood cancers like acute myelocytic Leukemia, acute lymphocytic leukemia and myelodysplastic syndrome. The therapeutic candidate comprises of autologous T cells engineered to express a T-cell receptor (TCR) that targets HA-2 antigen. The drug candidate is developed based on the TScan platform technology. It is administered by intravenous route.
TScan Therapeutics overview
TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of TSC-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.